Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Hideki Ueno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8600-1199; OpenAlex author ID A5054771200, A5107484373. Sources: OpenAlex.

Their work

Papers
44 (first author 4, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
130
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 1 paper · 2014: 1 paper · 2015: 4 papers · 2016: 1 paper · 2017: 2 papers · 2018: 5 papers · 2019: 6 papers · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: 4 papers · 2025: 5 papers · 2026: 4 papers

Papers 44

  1. Radiologic-pathologic discrepancy in the tumor size assessment of pancreatic ductal adenocarcinoma in the era of preoperative therapy. Co-author DOI 10.1007/s00595-026-03419-5↗
  2. Pancreatic cancer mimicking ectopic pancreas origin: a rare case after neonatal pyloromyotomy. Co-author DOI 10.1007/s12328-026-02352-x↗
  3. Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP0… Co-author DOI 10.1097/sla.0000000000006730↗
  4. Clinical benefit of locoregional therapy for oligometastasis after surgery for pancreatic cancer: a single center retrospective study. Co-author DOI 10.1186/s12885-026-16566-2↗
  5. Risk of hepatic steatosis with the preoperative treatment of pancreatic cancer and the short-term postoperative outcomes. Last author DOI 10.1007/s00595-024-02895-x↗
  6. Postoperative recurrence of pancreatic cancer controlled for 9 months solely by severe carbohydrate restriction: ketogenic diet. Co-author DOI 10.1007/s12328-025-02221-z↗
  7. A novel scoring system for prognostic stratification of node-positive pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gassur.2025.102187↗
  8. Surgery based on resectability status of pancreatic cancer: a narrative review. Co-author DOI 10.1093/jjco/hyaf131↗
  9. Dissecting Tumor Size Underestimation in Pancreatic Cancer: A Comparative Analysis of Preoperative Treatments. Last author DOI 10.1245/s10434-025-16917-6↗
  10. Impact of the COVID-19 pandemic on short-term outcomes after pancreaticoduodenectomy for pancreatic cancer: A retrospective study from the Japanese National Cl… Co-author DOI 10.1002/ags3.12798↗
  11. Evaluation of the Treatment Duration of Japanese Patients With Pancreatic Cancer in a Real-World Setting Using a Large Hospital Claims Database: The SUISEI Stu… Co-author DOI 10.1097/mpa.0000000000002321↗
  12. Preoperative CA19‑9 level and dual time point FDG‑PET/CT as strong biological indicators of borderline resectability in pancreatic cancer: A retrospective stud… Co-author DOI 10.3892/ol.2024.14412↗
  13. Pancreatic cancer with liver metastasis maintaining complete response with gemcitabine monotherapy: A case report. Co-author DOI 10.3892/ol.2024.14503↗
  14. Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience. Co-author DOI 10.3390/cancers15041101↗
  15. Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study. Co-author DOI 10.1186/s12885-022-10116-2↗
  16. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… Co-author DOI 10.1186/s13063-022-06049-7↗
  17. Clinical Impact of Dual Time Point 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer. Co-author DOI 10.3390/cancers14153688↗
  18. A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. First author DOI 10.1007/s10147-021-02001-y↗
  19. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Co-author DOI 10.1097/mpa.0000000000001702↗
  20. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Co-author DOI 10.1016/j.pan.2020.07.006↗
  21. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE tri… Co-author DOI 10.1016/j.ejca.2018.10.004↗
  22. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japa… Co-author DOI 10.1016/j.pan.2019.01.001↗
  23. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Co-author DOI 10.1093/jjco/hyy190↗
  24. Pathomorphological features of metastatic lymph nodes as predictors of postoperative prognosis in pancreatic cancer. Co-author DOI 10.1097/md.0000000000014369↗
  25. Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.26633↗
  26. Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Panc… Co-author DOI 10.2169/internalmedicine.2362-18↗
  27. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. Co-author DOI 10.1007/s00535-018-1466-y↗
  28. Measurement of copy number of ACTN4 to optimize the therapeutic strategy for locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.06.003↗
  29. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic … Co-author DOI 10.1016/j.pan.2018.07.007↗
  30. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Co-author DOI 10.1097/mpa.0000000000001049↗
  31. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. First author DOI 10.1097/mpa.0000000000001052↗
  32. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patien… Co-author DOI 10.1007/s00280-017-3250-8↗
  33. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… Co-author DOI 10.1136/esmoopen-2016-000151↗
  34. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-016-2972-3↗
  35. ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer. First author DOI 10.1038/bjc.2014.623↗
  36. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Co-author DOI 10.1038/srep18425↗
  37. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Co-author DOI 10.1111/cas.12674↗
  38. [A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic … Co-author PMID 25812499↗
  39. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. Co-author DOI 10.1002/jhbp.130↗
  40. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗
  41. Gemcitabine-induced pleuropericardial effusion in a patient with pancreatic cancer. Co-author DOI 10.1093/jjco/hys099↗
  42. [Pancreatic tumor: progress in diagnosis and treatment. Topics: I. Pancreatic carcinoma; 4. Progress of non-surgical treatment for pancreatic cancer]. Co-author DOI 10.2169/naika.101.29↗
  43. [Systemic chemotherapy and chemoradiotherapy for advanced pancreatic cancer]. Co-author PMID 22421761↗
  44. [Current status and future prospect of pre- and post-operative adjuvant therapy of pancreatic cancer: discussion]. First author PMID 23035336↗

Closest collaborators

The 25 strongest of 130 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takahiro Einama · 14 shared papers, 2019–2026 · strength 3.05
  2. Yoji Kishi · 13 shared papers, 2022–2026 · strength 2.96
  3. Kazuki Kobayashi · 6 shared papers, 2024–2025 · strength 1.38
  4. Kazuki Kobayashi · 5 shared papers, 2022–2026 · strength 1.02
  5. Takuji Okusaka · 16 shared papers, 2012–2021 · strength 0.93
  6. Michiaki Unno · 6 shared papers, 2011–2026 · strength 0.84
  7. Nobumasa Mizuno · 10 shared papers, 2015–2021 · strength 0.75
  8. Mayuko Ohara · 3 shared papers, 2024–2026 · strength 0.72
  9. Koki Ichio · 3 shared papers, 2024–2026 · strength 0.72
  10. Junji Furuse · 9 shared papers, 2013–2021 · strength 0.62
  11. Makoto Ueno · 7 shared papers, 2016–2021 · strength 0.59
  12. Tatsuya Ioka · 9 shared papers, 2013–2021 · strength 0.57
  13. Masafumi Ikeda · 9 shared papers, 2013–2021 · strength 0.57
  14. Akira Fukutomi · 8 shared papers, 2013–2021 · strength 0.55
  15. Sohei Satoi · 5 shared papers, 2011–2026 · strength 0.52
  16. Fuyuhiko Motoi · 4 shared papers, 2011–2026 · strength 0.49
  17. Masayuki Sho · 5 shared papers, 2013–2026 · strength 0.45
  18. Satoshi Kobayashi · 5 shared papers, 2018–2021 · strength 0.43
  19. Masato Ozaka · 6 shared papers, 2014–2020 · strength 0.43
  20. Ippei Matsumoto · 3 shared papers, 2019–2026 · strength 0.42
  21. Hideyuki Yoshitomi · 2 shared papers, 2022–2026 · strength 0.37
  22. Tsutomu Fujii · 2 shared papers, 2022–2026 · strength 0.37
  23. Chigusa Morizane · 6 shared papers, 2012–2021 · strength 0.34
  24. Tomoo Kosuge · 2 shared papers, 2019–2026 · strength 0.34
  25. Keita Wada · 2 shared papers, 2019–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.